Underutilization of the CROSS regimen among US radiation oncologists

A national survey of practice patterns

David A. Elliott, Shushan R. Rana, Nima Nabavizadeh, Yiyi Chen, Aaron Kusano, John Holland, Timur Mitin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: To examine patterns of clinical practice in locally advanced esophageal cancer among US radiation oncologists after publication of the CROSS trial. Materials and Methods: US radiation oncologists were surveyed on 13 questions pertaining to the management of esophageal cancer. Respondents' demographics and their clinical rationale were analyzed for statistical association with their treatment recommendations. Results: Few respondents (15%) offered the CROSS regimen to patients considered suitable surgical candidates, while a near-equivalent number (16%) prescribed between 41.4 and 50.4 Gy contingent upon radiation planning parameters. Among respondents who prescribed 50.4 Gy, 50% and 17% reported concurrent administration of carboplatin/paclitaxel and cisplatin/5-FU, respectively. Higher radiation doses, over 50.4 Gy, were utilized by 15% and 38% of respondents for borderline surgical candidates and candidates unfit for surgery, respectively. The majority of respondents believed that higher complete pathological response and R0 resection would be achieved, as well as higher toxicity conferred using 50.4 Gy instead of 41.4 Gy. A clinical trial comparing 41.4 Gy to 50.4 Gy with concurrent carboplatin/paclitaxel was supported by 76% of respondents. Conclusion: Despite results from the CROSS trial, the majority of responding US radiation oncologists do not offer 41.4 Gy with concurrent chemotherapy for surgically-fit patients with locally advanced esophageal cancer, believing that a higher dose will translate to improved response.

Original languageEnglish (US)
Pages (from-to)6375-6379
Number of pages5
JournalAnticancer Research
Volume38
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Esophageal Neoplasms
Carboplatin
Physicians' Practice Patterns
Radiation
Paclitaxel
Fluorouracil
Publications
Radiation Oncologists
Surveys and Questionnaires
Demography
Clinical Trials
Drug Therapy
Therapeutics

Keywords

  • Chemoradiotherapy
  • Esophageal cancer
  • Practice patterns
  • Radiation dose
  • Survey

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Underutilization of the CROSS regimen among US radiation oncologists : A national survey of practice patterns. / Elliott, David A.; Rana, Shushan R.; Nabavizadeh, Nima; Chen, Yiyi; Kusano, Aaron; Holland, John; Mitin, Timur.

In: Anticancer Research, Vol. 38, No. 11, 01.11.2018, p. 6375-6379.

Research output: Contribution to journalArticle

Elliott, David A. ; Rana, Shushan R. ; Nabavizadeh, Nima ; Chen, Yiyi ; Kusano, Aaron ; Holland, John ; Mitin, Timur. / Underutilization of the CROSS regimen among US radiation oncologists : A national survey of practice patterns. In: Anticancer Research. 2018 ; Vol. 38, No. 11. pp. 6375-6379.
@article{678eb22fb0de45ac87cb19bfda61659e,
title = "Underutilization of the CROSS regimen among US radiation oncologists: A national survey of practice patterns",
abstract = "Aim: To examine patterns of clinical practice in locally advanced esophageal cancer among US radiation oncologists after publication of the CROSS trial. Materials and Methods: US radiation oncologists were surveyed on 13 questions pertaining to the management of esophageal cancer. Respondents' demographics and their clinical rationale were analyzed for statistical association with their treatment recommendations. Results: Few respondents (15{\%}) offered the CROSS regimen to patients considered suitable surgical candidates, while a near-equivalent number (16{\%}) prescribed between 41.4 and 50.4 Gy contingent upon radiation planning parameters. Among respondents who prescribed 50.4 Gy, 50{\%} and 17{\%} reported concurrent administration of carboplatin/paclitaxel and cisplatin/5-FU, respectively. Higher radiation doses, over 50.4 Gy, were utilized by 15{\%} and 38{\%} of respondents for borderline surgical candidates and candidates unfit for surgery, respectively. The majority of respondents believed that higher complete pathological response and R0 resection would be achieved, as well as higher toxicity conferred using 50.4 Gy instead of 41.4 Gy. A clinical trial comparing 41.4 Gy to 50.4 Gy with concurrent carboplatin/paclitaxel was supported by 76{\%} of respondents. Conclusion: Despite results from the CROSS trial, the majority of responding US radiation oncologists do not offer 41.4 Gy with concurrent chemotherapy for surgically-fit patients with locally advanced esophageal cancer, believing that a higher dose will translate to improved response.",
keywords = "Chemoradiotherapy, Esophageal cancer, Practice patterns, Radiation dose, Survey",
author = "Elliott, {David A.} and Rana, {Shushan R.} and Nima Nabavizadeh and Yiyi Chen and Aaron Kusano and John Holland and Timur Mitin",
year = "2018",
month = "11",
day = "1",
doi = "10.21873/anticanres.12996",
language = "English (US)",
volume = "38",
pages = "6375--6379",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Underutilization of the CROSS regimen among US radiation oncologists

T2 - A national survey of practice patterns

AU - Elliott, David A.

AU - Rana, Shushan R.

AU - Nabavizadeh, Nima

AU - Chen, Yiyi

AU - Kusano, Aaron

AU - Holland, John

AU - Mitin, Timur

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Aim: To examine patterns of clinical practice in locally advanced esophageal cancer among US radiation oncologists after publication of the CROSS trial. Materials and Methods: US radiation oncologists were surveyed on 13 questions pertaining to the management of esophageal cancer. Respondents' demographics and their clinical rationale were analyzed for statistical association with their treatment recommendations. Results: Few respondents (15%) offered the CROSS regimen to patients considered suitable surgical candidates, while a near-equivalent number (16%) prescribed between 41.4 and 50.4 Gy contingent upon radiation planning parameters. Among respondents who prescribed 50.4 Gy, 50% and 17% reported concurrent administration of carboplatin/paclitaxel and cisplatin/5-FU, respectively. Higher radiation doses, over 50.4 Gy, were utilized by 15% and 38% of respondents for borderline surgical candidates and candidates unfit for surgery, respectively. The majority of respondents believed that higher complete pathological response and R0 resection would be achieved, as well as higher toxicity conferred using 50.4 Gy instead of 41.4 Gy. A clinical trial comparing 41.4 Gy to 50.4 Gy with concurrent carboplatin/paclitaxel was supported by 76% of respondents. Conclusion: Despite results from the CROSS trial, the majority of responding US radiation oncologists do not offer 41.4 Gy with concurrent chemotherapy for surgically-fit patients with locally advanced esophageal cancer, believing that a higher dose will translate to improved response.

AB - Aim: To examine patterns of clinical practice in locally advanced esophageal cancer among US radiation oncologists after publication of the CROSS trial. Materials and Methods: US radiation oncologists were surveyed on 13 questions pertaining to the management of esophageal cancer. Respondents' demographics and their clinical rationale were analyzed for statistical association with their treatment recommendations. Results: Few respondents (15%) offered the CROSS regimen to patients considered suitable surgical candidates, while a near-equivalent number (16%) prescribed between 41.4 and 50.4 Gy contingent upon radiation planning parameters. Among respondents who prescribed 50.4 Gy, 50% and 17% reported concurrent administration of carboplatin/paclitaxel and cisplatin/5-FU, respectively. Higher radiation doses, over 50.4 Gy, were utilized by 15% and 38% of respondents for borderline surgical candidates and candidates unfit for surgery, respectively. The majority of respondents believed that higher complete pathological response and R0 resection would be achieved, as well as higher toxicity conferred using 50.4 Gy instead of 41.4 Gy. A clinical trial comparing 41.4 Gy to 50.4 Gy with concurrent carboplatin/paclitaxel was supported by 76% of respondents. Conclusion: Despite results from the CROSS trial, the majority of responding US radiation oncologists do not offer 41.4 Gy with concurrent chemotherapy for surgically-fit patients with locally advanced esophageal cancer, believing that a higher dose will translate to improved response.

KW - Chemoradiotherapy

KW - Esophageal cancer

KW - Practice patterns

KW - Radiation dose

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85056126549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056126549&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12996

DO - 10.21873/anticanres.12996

M3 - Article

VL - 38

SP - 6375

EP - 6379

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -